




RealRate

PHARMACEUTICAL 2022

Biofrontera Inc.
Rank 385 of 466

us.com the alternative.com
PERFECT FOR AMERICAN COMPANIES AND WEBSITES TARGETING THE AMERICAN MARKET



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Biofrontera Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biofrontera Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 46% points. The greatest weakness of Biofrontera Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is -38%, being 116% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	46,421
Cost of Goods Sold	0
Intangible Assets	3,450
Liabilities, Current	13,836
Liabilities, Non-Current	5,649
Other Assets	3,081
Other Compr. Net Income	0
Other Expenses	12,845
Other Liabilities	22,396
Other Net Income	-12,456
Other Revenues	24,100
Property and Equipment	267
Research and Development	0
Selling, General and Administrative Expense	36,512

Output Variable	Value in 1000 USD
Assets	53,219
Liabilities	41,881
Expenses	49,357
Revenues	24,100
Stockholders Equity	11,338
Net Income	-37,713
Comprehensive Net Income	-37,713
Economic Capital Ratio	-38%